Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Rhea-AI Summary

Nyxoah, a medical technology company specializing in innovative solutions for Obstructive Sleep Apnea (OSA), announced its participation in the Cantor 2021 Global Healthcare Conference on September 28, 2021, at 4:00 pm CET/10:00 am ET. CEO Olivier Taelman will present virtually, and a live webcast will be available on the company’s investor relations website. Nyxoah is known for its lead product, the Genio® system, which received the European CE Mark in 2019 following the successful BLAST OSA study. The company is also conducting the DREAM IDE pivotal study for FDA approval.

Positive

• Successful completion of the BLAST OSA study, leading to European CE Mark for the Genio® system.
• Recent positive outcomes from the BETTER SLEEP study enabling potential expansion to Complete Concentric Collapse patients.
• Conducting the DREAM IDE pivotal study for FDA approval, indicating growth and market expansion prospects.

Negative

• None.

Nyxoah Announces Participation in the Cantor 2021 Virtual Global Healthcare Conference

Mont-Saint-Guibert (Belgium), September 13, 2021, 10:30 pm CET / 4:30 pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Olivier Taelman, Chief Executive Officer, will participate at the Cantor 2021 Global Healthcare Conference on Tuesday, September 28, 2021, with a virtual presentation at 4:00 pm CET/10:00 am ET.

A live webcast and replay of this event will be available on the Company’s investors relations website at https://investors.nyxoah.com/

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah is seeking for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
vivian.cervantes@gilmartinir.com

Attachment

• ENGLISH - NYXH Announces Cantor HC - FINAL

FAQ

When is Nyxoah participating in the Cantor 2021 Global Healthcare Conference?

Nyxoah will participate on September 28, 2021, at 4:00 pm CET/10:00 am ET.

What is the focus of Nyxoah's business?

Nyxoah focuses on innovative solutions to treat Obstructive Sleep Apnea (OSA).

What product is Nyxoah known for?

Nyxoah is known for the Genio® system, a hypoglossal neurostimulation therapy.

What studies have supported Nyxoah's product development?

The BLAST OSA and BETTER SLEEP studies have supported the development of the Genio® system.

What is the current status of Nyxoah's FDA approval process?

Nyxoah is currently conducting the DREAM IDE pivotal study for FDA approval.